Downloadable Living Slideset

Share

Program Content

Activities

  • HER2-Targeted Therapy in NSCLC
    Improving Outcomes for Patients With Advanced NSCLC Through the Optimal Integration of HER2-Targeted Antibody–Drug Conjugate Therapy
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 25, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.